12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Corluxin mifepristone regulatory update

Corcept disclosed in its 3Q13 earnings that it submitted an MAA to EMA for Corluxin mifepristone to treat endogenous Cushing's syndrome. Corcept expects feedback from EMA...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >